Accipiter Biosciences

About Accipiter Biosciences

Accipiter Biosciences designs and develops de novo protein therapies to address complex diseases like autoimmune disorders and cancer. Their mission is to create single-agent biologics that engage multiple pathways, overcoming the limitations of traditional combination therapies through computational protein design.

Products & Services

De Novo Biologics:Custom-engineered proteins combining multiple therapeutic mechanisms in one stable molecule, designed to activate cell-surface receptors simultaneously.

Versatile Platform:A computational protein design platform using in silico methods to create multifunctional proteins for therapeutic applications, with rapid design-to-testing cycles of less than 2 months.

Specialties

Computational Protein Design De Novo Protein Therapies Multifunctional Biologics Therapeutic Applications for Complex Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 12700000 MR: - FA: 12.7 million FAN: 12700000	D: 2025-11-06 FD: 2025-11-06	8 investors

Seed Latest

2025-11-06

$12.7M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Matthew Bick

Chief Executive Officer

LinkedIn (Pro only)

J

Javier Castellanos

Chief Technology Officer

LinkedIn (Pro only)

H

Hector Rincon-Arano

Chief Scientific Officer

LinkedIn (Pro only)

W

William J. Canestaro

Chief Strategy Officer/Chief Operations Officer

R

Randy Schatzman

President and CEO at Bolt Biotherapeutics, Chairman

J

Jiaping Gu

Partner at Takeda Ventures

View 11 more team members with Pro

Unlock Full Team Directory

Recent News